NOVAVAX INC

During the three months ended June 30, 2024, certain of our directors and “officers” (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended)adopted orterminated contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended, for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. We refer to these contracts, instructions and written plans as “Rule 10b5-1 trading plans” and each one as a “Rule 10b5-1 trading plan.” We describe the material terms of these Rule 10b5-1 trading plans below.

John C. Jacobs, President and Chief Executive Officer

On May 28, 2024, John C. Jacobs, our President and Chief Executive Officer and a member of our board of directors, entered into a Rule 10b5-1 trading plan that provides that Mr. Jacobs, acting through a broker, may sell up to an aggregate of 47,526 shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from August 27, 2024 to April 30, 2025. The plan is scheduled to terminate on April 30, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Jacobs or the broker, or as otherwise provided in the plan.

John Trizzino, President and Chief Operating Officer

On June 17, 2024, John Trizzino, our President and Chief Operating Officer, entered into a Rule 10b5-1 trading plan that provides that Mr. Trizzino, acting through a broker, may sell up to an aggregate of 218,669 shares of our common stock, subject to adjustments for stock splits, stock combinations, stock dividends and other similar changes to our common stock. Sales of shares under the plan may only occur from September 16, 2024 to May 7, 2025. The plan is scheduled to terminate on May 7, 2025, subject to earlier termination upon the sale of all shares subject to the plan, upon termination by Mr. Trizzino or the broker, or as otherwise provided in the plan.

Filip Dubovsky, MD, Former President, Research & Development

On May 10, 2024 , Filip Dubovsky, MD, our former President, Research & Development, terminated a Rule 10b5-1 trading plan that he had originally adopted on December 12, 2023. The plan was for the sale of up to 13,365 shares of our common stock. Sales under the plan were scheduled to occur from March 15, 2024 to June 14, 2024.